Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial

BACKGROUND: Despite renin–angiotensin–aldosterone system blockade and immunosuppressive treatment, focal segmental glomerulosclerosis (FSGS) often progresses to kidney failure. The objective of this prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disea...

Descripción completa

Detalles Bibliográficos
Autores principales: Wheeler, David C, Jongs, Niels, Stefansson, Bergur V, Chertow, Glenn M, Greene, Tom, Hou, Fan Fan, Langkilde, Anna Maria, McMurray, John J V, Rossing, Peter, Nowicki, Michal, Wittmann, István, Correa-Rotter, Ricardo, Sjöström, C David, Toto, Robert D, Heerspink, Hiddo J L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395378/
https://www.ncbi.nlm.nih.gov/pubmed/34850160
http://dx.doi.org/10.1093/ndt/gfab335

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395378/
https://www.ncbi.nlm.nih.gov/pubmed/34850160
http://dx.doi.org/10.1093/ndt/gfab335

Ejemplares similares